Alterola Biotech (ABTI) 10-K 17 Jul 24 2024 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Mar. 31, 2024	Jun. 28, 2024	Sep. 30, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--03-31
Entity File Number	333-156091
Entity Registrant Name	Alterola Biotech, Inc.
Entity Central Index Key	0001442999
Entity Tax Identification Number	82-1317032
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	47 Hamilton Square
Entity Address, City or Town	Birkenhead Merseyside
Entity Address, Country	GB
Entity Address, Postal Zip Code	CH415AR
City Area Code	151
Local Phone Number	601 9477
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 252,884
Entity Common Stock, Shares Outstanding		1,467,475,452
Document Financial Statement Error Correction [Flag]	false
Auditor Name	Green Growth CPAs
Auditor Location	Los Angeles, Ca
Auditor Firm ID	6580

CONSOLIDATED BALANCE SHEETS (Au

CONSOLIDATED BALANCE SHEETS (Audited) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Current Assets
Bank	$ 2,654	$ 8,899
VAT receivable		36,426
Deferred tax asset
Inventories	1,009	990
Total Current Assets	3,663	46,315
Intangible assets		12,000,000
TOTAL ASSETS	3,663	12,046,315
Current Liabilities
Accounts payable	825,210	613,729
Accrued expenses	362,451	259,960
Loan payable, related party	145,603	1,256,641
Total Current Liabilities	1,333,264	2,130,330
Convertible Note  Payable		154,841
Total Liabilities	1,333,264	2,285,171
Stockholders’ Equity (Deficit)
Preferred Stock, $.001 par value, 10,000,000 shares authorized, -0- shares issued and outstanding
Common Stock, $.001 par value, 2,000,000,000 shares authorized, 1,382,662,952 and 807,047,948 shares issued and outstanding, respectively	1,382,644	807,048
Additional paid-in capital	9,663,970	18,927,919
Accumulated deficit	(12,416,075)	(10,041,696)
Foreign currency translation adjustment	39,860	67,873
Total Stockholders’ Equity (Deficit)	(1,329,601)	9,761,144
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 3,663	$ 12,046,315

CONSOLIDATED BALANCE SHEETS (_2

CONSOLIDATED BALANCE SHEETS (Audited) (Parenthetical)	Mar. 31, 2024 $ / shares shares
Statement of Financial Position [Abstract]
Preferred Stock, Par or Stated Value Per Share | $ / shares	$ 0.001
Preferred Stock, Shares Authorized	10,000,000
Preferred Stock, Shares Outstanding	0
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.001
Common Stock, Shares Authorized	2,000,000,000
Common Stock, Shares, Outstanding	1,382,662,952

AUDITED CONSOLIDATED STATEMENT

AUDITED CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Accounting and audit fees	118,257	118,611
Professional fees	288,904	363,944
Research and development	28,770	181,805
Legal fees	73,838	179,846
Directors fees and expenses	227,575	546,903
Consulting fees	994,051	442,354
Salaries and wages	124,924	131,664
General and administrative expenses	251,999	67,719
TOTAL OPERATING EXPENSES	2,108,318	2,032,846
LOSS FROM OPERATIONS	(2,108,318)	(2,032,846)
OTHER INCOME (EXPENSE)
Impairment losses of intangible assets	(392,278)
Impairment losses of deferred tax asset	(39,567)	(20,484)
Gain on forgiveness of debt	138,137
Foreign exchange influences	27,647	(17,856)
TOTAL OTHER INCOME (EXPENSE)	(266,061)	(38,340)
PROVISION FOR INCOME TAXES
NET LOSS	$ (2,374,379)	$ (2,071,186)
NET LOSS PER SHARE: BASIC AND DILUTED	$ 0	$ 0
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED	1,051,629,613	807,047,948
Foreign translation adjustment	$ (28,013)	$ 53,274
Comprehensive Loss	$ (2,402,392)	$ (2,017,912)

AUDITED CONSOLIDATED STATEMEN_2

AUDITED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT - USD ($)	Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	Stock Subscription [Member]	Comprehensive Income [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Mar. 31, 2022	$ 802,633		$ 17,942,833	$ 136,721	$ 14,599	$ (7,970,510)	$ 10,926,276
Shares, Issued at Mar. 31, 2022	802,633,333
Change in foreign currency					53,274		53,274
Shares issued for cash	$ 385		49,615				50,000
Stock Issued During Period, Shares, New Issues	384,615
Shares issued for settlement of debt	$ 280		136,721	(136,721)			280
Stock Issued During Period, Shares, Other	280,000
Shares issued for services	$ 1,500		319,500				321,000
Stock Issued During Period, Shares, Issued for Services	1,500,000
Shares issued for services - Directors	$ 2,250		479,250				481,500
Stock Issued During Period, Shares, Employee Benefit Plan	2,250,000
Net loss for the period						(2,071,186)	(2,071,186)
Ending balance, value at Mar. 31, 2023	$ 807,048		18,927,919		67,873	(10,041,696)	9,761,144
Shares, Issued at Mar. 31, 2023	807,047,948
Change in foreign currency					(28,013)		(28,013)
Shares issued for settlement of debt	$ 476	$ (476)	157,339				157,339
Stock Issued During Period, Shares, Other	476,000	(476,000)
Shares issued for services	$ 16,088	$ (16,088)	305,652				305,652
Stock Issued During Period, Shares, Issued for Services	16,088,000	(16,088,000)
Shares issued for services - Directors	$ 9,000	$ (9,000)	171,000				171,000
Stock Issued During Period, Shares, Employee Benefit Plan	9,000,000	(9,000,000)
Net loss for the period						(2,374,379)	(2,374,379)
Shares reclaimed into Treasury shares	$ (44,064)	$ 44,064
Stock Issued During Period, Shares, Treasury Stock Reissued	(44,064,000)	44,064,000
Shares issued for exercise of warrants	$ 13,500	$ (13,500)
Stock Issued During Period, Shares, Conversion of Convertible Securities	13,500,000	(13,500,000)
Shares issued for acquisition of Alinova Biosciences	$ 5,000	$ (5,000)	295,000				295,000
Stock Issued During Period, Shares, Acquisitions	5,000,000	(5,000,000)
Shares reclaimed from asset acquisition cancellation	$ (24,000)	$ 24,000	(12,000,000)				(12,000,000)
[custom:StockReclaimedDuringPeriodSharesAcquisitionCancellation]	(24,000,000)	24,000,000
Additional shares reclaimed from asset acquisition cancellation	$ (5,016)	$ 5,016
[custom:StockReclaimedAdditionalDuringPeriodSharesAcquisitionCancellation]	(5,015,996)	5,015,996
Shares issued for conversion of debt	$ 587,500	$ (29,016)	1,762,500				2,320,984
[custom:StockIssuedDuringPeriodSharesConversionOfDebt]	587,499,996	(29,015,996)
Shares issued for services	$ 8,360		21,737				30,097
[custom:StockIssuedDuringPeriodSharesOutsideServices]	8,360,306
Shares issued for services - management	$ 8,771		22,804				31,575
[custom:StockIssuedDuringPeriodSharesInternalServices]	8,770,695
Ending balance, value at Mar. 31, 2024	$ 1,382,663		$ 9,663,951		$ 39,860	$ (12,416,075)	$ (1,329,601)
Shares, Issued at Mar. 31, 2024	1,382,662,949

AUDITED CONSOLIDATED STATEMEN_3

AUDITED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period	$ (2,374,379)	$ (2,071,186)
Adjustments to reconcile net loss to net cash flows used in operating activities
Shares issued for services	538,324	802,500
Changes in assets and liabilities:
Funds in attorney trust		12,414
Inventory	(19)	60
VAT receivable	65,110	14,260
Accounts payable	221,385	71,219
Accrued liabilities	102,491	(136,531)
Net Cash Used in Operating Activities	(1,447,088)	(1,307,264)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from share issuance		50,281
Loan from related parties	1,468,856	1,148,792
Net Cash Provided by Financing Activities	1,468,856	1,199,073
Net change in cash	21,768	(108,191)
Foreign currency change	(28,013)	53,274
Cash and cash equivalents, beginning of period	8,899	63,816
Cash and cash equivalents, end of period	2,654	8,899
NON-CASH INVESTING AND FINANCING INFORMATION
Return of intangible assets	12,000,000
Impairment of deferred tax asset	39,567	20,484
Impairment of intangible assets	392,278
Gain on debt conversion	138,163
Shares issued for conversion of debt	$ 2,320,984

NOTE 1_ NATURE OF BUSINESS

NOTE 1– NATURE OF BUSINESS	12 Months Ended
	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NOTE 1– NATURE OF BUSINESS	NOTE 1– NATURE OF BUSINESS After formation, the Company was in the business of mineral exploration. On May 3, 2010, the Company sold its mineral exploration business and entered into an Intellectual Property Assignment Agreement (“IP Agreement”) with Soren Nielsen pursuant to which Mr. Nielsen transferred his right, title and interest in all intellectual property relating to certain chewing gum compositions having appetite suppressant activity (the “IP”) to the Company for the issuance of 55,000,000 Following the acquisition of the IP the Company changed its business direction to pursue the development of chewing gums for the delivery of Nutraceutical/functional ingredients for applications such as appetite suppressant, cholesterol suppressant, vitamin delivery, antioxidant delivery and motion sickness suppressant. On January 19, 2021, the Company entered into an Stock Purchase Agreement (the “Agreement”) with ABTI Pharma Limited, a company registered in England and Wales (“ABTI Pharma”), pursuant to which the Company agreed to acquire all of the outstanding shares of capital stock of ABTI Pharma from its shareholders in exchange for 600,000,000 The transaction is being accounted for as a reverse acquisition and recapitalization. ABTI Pharma is the acquirer for accounting purposes and the Company is the issuer. The historical financial statements presented are the financial statements of ABTI. The Agreement was treated as a recapitalization and not as a business combination; at the date of the acquisition, the net liabilities of the legal acquirer, Alterola, were $389,721 The business plan of the company is no longer focused on a chewing gum delivery system but was re-focused on the development of cannabinoid, cannabinoid-like, and non-cannabinoid pharmaceutical active pharmaceutical ingredients (APIs), pharmaceutical medicines made from cannabinoid, cannabinoid-like, and non-cannabinoid APIs and European novel food approval of cannabinoid-based, cannabinoid-like and non-cannabinoid ingredients and products .In addition, the company plans to develop such bulk ingredients for supply into the cosmetic sector. On December 2, 2021, the Company closed an Asset Purchase Agreement (the “Purchase Agreement”) with C2 Wellness Corp., a Wyoming corporation, and Dr. G. Sridhar Prasad (together, the “Seller”) and acquired certain IP assets (the “Assets”) from Seller, which include: • Novel cannabinoid molecules and their associated intellectual property; • Novel cannabinoid pro-drugs, and their associated intellectual property; • Novel proprietary cannabinoid formulations, designed to target lymphatic delivery, and their associated intellectual property; • Novel proprietary nano-encapsulated cannabinoid formulations, in self-dissolving polymers, and their associated intellectual property; and • Cannabinoids and cannabinoid pro-drug formulations for topical ocular delivery, and their associated intellectual property. In exchange for the Assets, the Company issued to Seller shares of common stock. On September 8, 2023, the Company and Seller entered into an Agreement to sell the assets, such that the Company sold the assets back to the Seller and the Seller paid 29,015,993 As of April 18, 2023, we acquired intellectual property from Alinova Biosciences Ltd. We acquired Alinova’s joint interest in the patent family of PTX 0001. We paid 35,000 5,000,000 LIQUIDITY & GOING CONCERN Alterola has negative working capital of $1,329,601 $12,416,075 The ability of Alterola to continue as a going concern is dependent on the Company generating cash from the sale of its common stock and/or obtaining debt financing and attaining future profitable operations. Management’s plans include selling its equity securities and obtaining debt financing to fund its capital requirement and ongoing operations; however, there can be no assurance the Company will be successful in these efforts.

NOTE 2 _ SUMMARY OF SIGNIFICANT

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Restatement During the year ended March 31, 2024, the Company identified that the deferred tax asset and capitalized intangible costs recorded during the year ended March 31, 2023 should have been removed from the balance sheet. Additionally, the company reperformed their cumulative translation adjustment summary and recorded adjustments related to this. The company recorded entries and the impact of these entries was as follows: NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement Summary (Details) 3/31/2023 (as restated) 3/31/2023 Differences Assets 12,046,315 12,376,963 (330,648 ) Liabilities 2,285,171 2,281,416 3,755 Equity 9,761,144 10,095,547 (334,403 ) CTA 67,873 (63,173 ) 131,046 Result of the year (2,071,186 ) (1,742,457 ) (328,729 ) 3/31/2023 (as restated) 3/31/2023 Differences Net cash provided by operating activities (1,307,264 ) (1,039,792 ) (267,472 ) Net cash used by investing activities — (139,799 ) 139,799 Net cash provided by financing activities 1,199,073 1,212,159 (13,086 ) Net change in cash (108,191 ) 32,689 (140,880 ) Basis of Presentation The accompanying consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United State of America (GAAP accounting) and include the accounts of Alterola and its wholly owned subsidiaries ABTI Pharma, Phytotherapeutix Ltd, and Ferven Ltd. All material intercompany transactions and balances have been eliminated. The Company had a September 30 fiscal year end. Subsequent to the Agreement with ABTI Pharma , the Company has changed its year end from September 30 to March 31 effective July 13, 2021 Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATEDEDFINANCIAL STATEMENTS MARCH 31, 2024 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Cash and Equivalents For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents. Fair Value of Financial Instruments Alterola’s financial instruments consist of cash and equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value (“FV”) due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. FV is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The FV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the FV of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining FV, the disclosure requirements around FV establish a FV hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring FV are observable in the market. Each FV measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the FV measurement in its entirety. These levels are: Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The FV are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their FV due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Foreign Currency Translation The financial statements are presented in US Dollars. Transactions with foreign subsidiaries where US dollars are not the functional currency will be recorded in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830 Foreign Currency Transaction Comprehensive Income Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended March 31, 2022, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605. Loss Per Common Share Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments. Stock-Based Compensation Stock-based compensation is accounted for at FV in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options Research and development We engage in a variety of research and development activities to develop our technologies and work toward development of a saleable product. When it is determined that the research and development products we are creating have reached a point where saleable products are possible, these amounts are capitalized. As of March 31, 2024 and March 31 ,2023 there are no The research and development costs incurred by the company relate to the following: • Licenses for patent and know-how (Nano 4 M) - this relates to the company’s formulation of Active Pharmaceutical Ingredients ( API) for its lead pharmaceutical programs. • Protein Technologies Ltd – this relates to the company’s research into production of cannabinoids by biosynthesis (as opposed to botanical production by growing plants). The company has genetically modified an organism to produce cannabinoids by fermentation ( similar to methodology used for the production of antibiotics) ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Research and development (continued) • Apex Molecular Ltd.- the company has a number of pharmaceutical development programs using both novel and natural molecules. The Company employs third party chemistry / contract, manufacturing companies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. • Acquisition of intellectual property from Alinova Biosciences Ltd. • Continued patent prosecution and internationalization of company intellectual property. • Staff costs and consultancy costs relating to R & D. Other Intangible Assets We have recorded the assets acquired as part of the C2 Wellness acquisition and Alinova acquisition as indefinite lived Intangible assets. Indefinite life intangible assets recorded are not amortized and, as a result, are assessed for impairment at least annually, using either a qualitative or quantitative process. The C2 Wellness asset that was acquired was subsequently re-sold as discussed above. We performed this annual assessment as of March 31, 2024, noting impairment factors indicating possible impairment of intangible assets recognized and recorded impairment of $392,278 . Risks and Uncertainties On January 30, 2020, the World Health Organization declared the coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and business. The Coronavirus and actions taken to mitigate it have had an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company plans to operate. We may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, and fires. An outbreak of infectious disease, a pandemic or a similar public health threat or a fear of any of the foregoing, could adversely impact us by causing operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how we may be affected if such an epidemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results, and financial condition. Recent Accounting Pronouncements Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

NOTE 3 _ INTANGIBLE ASSETS

NOTE 3 – INTANGIBLE ASSETS	12 Months Ended
	Mar. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
NOTE 3 – INTANGIBLE ASSETS	NOTE 3 – INTANGIBLE ASSETS As part of the C2 Wellness acquisition, the company recognized $12,000,000 $12,139,779

NOTE 4 _ DEFERRED TAX ASSET

NOTE 4 – DEFERRED TAX ASSET	12 Months Ended
	Mar. 31, 2024
Income Tax Disclosure [Abstract]
NOTE 4 – DEFERRED TAX ASSET	NOTE 4 – DEFERRED TAX ASSET As of the year ended March 31, 2023, the Company had recorded $189,355

NOTE 5 _ ACCOUNTS PAYABLE

NOTE 5 – ACCOUNTS PAYABLE	12 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
NOTE 5 – ACCOUNTS PAYABLE	NOTE 5 – ACCOUNTS PAYABLE Accounts payable consisted of the following at March 31, 2024 and March 31, 2023: March 31, 2024 March 31, 2023 Accounting and audit $ 181,955 $ 149,613 Legal fees and transfer agent 85,627 59,565 Research and development 409,904 337,893 General and administrative 147,724 66,658 Total Accrued Expenses $ 825,210 $ 613,729 ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024

NOTE 6 _ ACCRUED EXPENSES

NOTE 6 – ACCRUED EXPENSES	12 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
NOTE 6 – ACCRUED EXPENSES	NOTE 6 – ACCRUED EXPENSES Accrued expenses consisted of the following at March 31, 2024 and March 31, 2023: March 31, 2024 March 31, 2023 Accounting and Audit $ 49,468 $ 15,000 Research and development — 9,432 General and administrative 89,508 128,325 Legal fees and transfer agent 223,475 107,203 Total Accrued Expenses $ 362,451 $ 259,960

NOTE 7 _ CAPITAL STOCK

NOTE 7 – CAPITAL STOCK	12 Months Ended
	Mar. 31, 2024
Equity [Abstract]
NOTE 7 – CAPITAL STOCK	NOTE 7 – CAPITAL STOCK The Company has 2,000,000,000 $0.001 10,000,000 $0.001 On August 11, 2021, the Company issued 15,000,000 $0.64 5 year $0.001 the total potential impact on the financial statements of the exercise of the warrants was approximately $1 million dollars June 13, 2023 The total potential impact on the financial statements of the exercise of the warrants was approximately $13,500. During September 2021, the Company received an investment for £100,000 Sterling (or $136,721 280,000 280,000 On October 29, 2021, the Company issued 7,500,000 $2,399,250 As pursuant to the asset purchase agreement dated November 9, 2021, the Company acquired certain intellectual property rights of C2 Wellness Corp. In exchanges for the assets acquired, the Company issued 24,000,000 $0.50 $12,000,000 On December 21, 2021, the company issued 520,000 $130,000 On February 8, 2022, the company issued 333,333 $50,000 $0.15 On or about March 3, 2022, the Company issued 16,000,000 $3,360,000 On April 5, 2022, the company issued 384,615 $50,000 $0.13 ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 NOTE 7 – CAPITAL STOCK (continued) On April 29, 2022, the Company issued 1,500,000 $0.214 $321,000 On May 2, 2022, the Company issued 280,000 $136,721 $0.50 $140,000 On May 4, 2022, we issued 2,250,000 On August 1, 2022, the Company issued 2,250,000 On June 6, 2023, the Company reclaimed 44,064,000 On June 13, 2023, we issued 13,500,000 15,000,000 On June 13, 2023, we issued 476,000 £125,000 On June 13, 2023, we issued 5,000,000 June 13, 2023, we issued 5,999,900 June 13, 2023, we issued 10,088,100 On June 14, 2023, we issued 9,000,000 On September 8, 2023, the Company entered into an Agreement to Return Assets and Shares with C2 Wellness Corp. As part of the agreement, the company received 29,015,993 24,000,000 5,015,996 $12,000,000 On October 16, 2023, the Company issued 587,499,996 $406,575 On December 21, 2023, the Company issued 17,131,001 $61,672 During the year ended March 31, 2024, the company reviewed the cumulative translation adjustment recorded on the financial statements and made corrections to the amount recorded for the year ended March 31, 2023 as discussed in the restatement footnote above. The updated number was recorded as $67,873 The Company had 1,382,662,952 807,047,948 ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024

NOTE 8 _ NOTES PAYABLE

NOTE 8 – NOTES PAYABLE	12 Months Ended
	Mar. 31, 2024
Debt Disclosure [Abstract]
NOTE 8 – NOTES PAYABLE	NOTE 8 – NOTES PAYABLE On September 21, 2021, the Company entered into a convertible note agreement with an outside party for $171,863 90 days with an interest fee of $13,680 The conversion option would be at 90 days, with share conversion at .50 cents, with an issuance of 340,000 shares, valued at $428,400 at the date of the loan 136,000 $171,000 476,000 Conversion of the debt is at a discount rate of 60% $1.37 On August 1, 2022, the Company issued a note payable for 90 days $75,000 2,250,000 $75,000 On June 13, 2023, we issued 476,000 £125,000

NOTE 9 _ RELATED PARTY TRANSACT

NOTE 9 – RELATED PARTY TRANSACTIONS	12 Months Ended
	Mar. 31, 2024
Related Party Transactions [Abstract]
NOTE 9 – RELATED PARTY TRANSACTIONS	NOTE 9 – RELATED PARTY TRANSACTIONS Alterola neither owns nor leases any real or personal property. An officer has provided office space as an arm’s length transaction with rental at commercial rates. There is no obligation for the officer to continue this arrangement. Such costs are immaterial to the financial statements and accordingly are not reflected herein. The officers and directors are involved in other business activities and most likely will become involved in other business activities in the future. During the year ended March 31, 2024, a shareholder made advances to the company to fund operating expenses in the amount of $694,847 These advances are non – interest bearing and have no specified terms of repayment

NOTE 10 _ SUBSEQUENT EVENTS

NOTE 10 – SUBSEQUENT EVENTS	12 Months Ended
	Mar. 31, 2024
Subsequent Events [Abstract]
NOTE 10 – SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS In accordance with ASC Topic 855-10, the Company analyzed its operations subsequent to March 31, 2024 to the date these financial statements were issued. We noted the following subsequent events. As part of an agreement dated March 12, 2024, Bright Green Corporation agreed to return 83,226,814 shares of common stock of Alterola to the three shareholders (Equipped4 Holdings Limited (“Equipped”), Phytotherapeutix Holdings Ltd. (“Phyto”), and TPR Global Limited (“TPR”)) who had initially sold the shares to Bright Green. This was in exchange for settlement of the $1,650,000 remaining balance for the shares as per the Agreement between the parties executed on October 03, 2022. Equipped, Phyto, and TPR each received approximately 27,742,271 shares of common stock of Alterola. The shares were transferred on June 03, 2024 On March 14, 2024, the Company received confirmation that the 10,088,100 shares held in escrow for Bridgeway Capital partners as a payment relating to services provided according to an Agreement between the parties dated June 24, 2022, was waived by Bridgeway Capital Partners.

NOTE 2 _ SUMMARY OF SIGNIFICA_2

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Restatement	Restatement During the year ended March 31, 2024, the Company identified that the deferred tax asset and capitalized intangible costs recorded during the year ended March 31, 2023 should have been removed from the balance sheet. Additionally, the company reperformed their cumulative translation adjustment summary and recorded adjustments related to this. The company recorded entries and the impact of these entries was as follows: NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement Summary (Details) 3/31/2023 (as restated) 3/31/2023 Differences Assets 12,046,315 12,376,963 (330,648 ) Liabilities 2,285,171 2,281,416 3,755 Equity 9,761,144 10,095,547 (334,403 ) CTA 67,873 (63,173 ) 131,046 Result of the year (2,071,186 ) (1,742,457 ) (328,729 ) 3/31/2023 (as restated) 3/31/2023 Differences Net cash provided by operating activities (1,307,264 ) (1,039,792 ) (267,472 ) Net cash used by investing activities — (139,799 ) 139,799 Net cash provided by financing activities 1,199,073 1,212,159 (13,086 ) Net change in cash (108,191 ) 32,689 (140,880 )
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United State of America (GAAP accounting) and include the accounts of Alterola and its wholly owned subsidiaries ABTI Pharma, Phytotherapeutix Ltd, and Ferven Ltd. All material intercompany transactions and balances have been eliminated. The Company had a September 30 fiscal year end. Subsequent to the Agreement with ABTI Pharma , the Company has changed its year end from September 30 to March 31 effective July 13, 2021
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATEDEDFINANCIAL STATEMENTS MARCH 31, 2024 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Cash and Equivalents	Cash and Equivalents For purposes of the statement of cash flows, the Company considers highly liquid financial instruments purchased with a maturity of three months or less to be cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Alterola’s financial instruments consist of cash and equivalents, accrued expenses, accrued interest and notes payable. The carrying amount of these financial instruments approximates fair value (“FV”) due either to length of maturity or interest rates that approximate prevailing market rates unless otherwise disclosed in these financial statements. FV is defined as the price that would be received upon sale of an asset or paid upon transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. The FV should be calculated based on assumptions that market participants would use in pricing the asset or liability, not on assumptions specific to the entity. In addition, the FV of liabilities should include consideration of non-performance risk including our own credit risk. In addition to defining FV, the disclosure requirements around FV establish a FV hierarchy for valuation inputs which is expanded. The hierarchy prioritizes the inputs into three levels based on the extent to which inputs used in measuring FV are observable in the market. Each FV measurement is reported in one of the three levels which is determined by the lowest level input that is significant to the FV measurement in its entirety. These levels are: Level 1 – inputs are based upon unadjusted quoted prices for identical instruments traded in active markets. Level 2 – inputs are based upon significant observable inputs other than quoted prices included in Level 1, such as quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The FV are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques. The carrying value of the Company’s financial assets and liabilities which consist of cash, accounts payable and accrued liabilities, and notes payable are valued using level 1 inputs. The Company believes that the recorded values approximate their FV due to the short maturity of such instruments. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest, exchange or credit risks arising from these financial instruments.
Income Taxes	Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
Foreign Currency Translation	Foreign Currency Translation The financial statements are presented in US Dollars. Transactions with foreign subsidiaries where US dollars are not the functional currency will be recorded in accordance with Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 830 Foreign Currency Transaction Comprehensive Income
Revenue Recognition	Revenue Recognition On January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers ("ASC 606"), using the modified retrospective method applied to those contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASC 605. As of and for the year ended March 31, 2022, the financial statements were not materially impacted as a result of the application of Topic 606 compared to Topic 605.
Loss Per Common Share	Loss Per Common Share Basic loss per share is calculated using the weighted-average number of common shares outstanding during each reporting period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The Company does not have any potentially dilutive instruments.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation is accounted for at FV in accordance with ASC Topic 718. To date, the Company has not adopted a stock option plan and has not granted any stock options
Research and development	Research and development We engage in a variety of research and development activities to develop our technologies and work toward development of a saleable product. When it is determined that the research and development products we are creating have reached a point where saleable products are possible, these amounts are capitalized. As of March 31, 2024 and March 31 ,2023 there are no The research and development costs incurred by the company relate to the following: • Licenses for patent and know-how (Nano 4 M) - this relates to the company’s formulation of Active Pharmaceutical Ingredients ( API) for its lead pharmaceutical programs. • Protein Technologies Ltd – this relates to the company’s research into production of cannabinoids by biosynthesis (as opposed to botanical production by growing plants). The company has genetically modified an organism to produce cannabinoids by fermentation ( similar to methodology used for the production of antibiotics) ALTEROLA BIOTECH, INC. NOTES TO THE UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS MARCH 31, 2024 NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) Research and development (continued) • Apex Molecular Ltd.- the company has a number of pharmaceutical development programs using both novel and natural molecules. The Company employs third party chemistry / contract, manufacturing companies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. • Acquisition of intellectual property from Alinova Biosciences Ltd. • Continued patent prosecution and internationalization of company intellectual property. • Staff costs and consultancy costs relating to R & D.
Other Intangible Assets	Other Intangible Assets We have recorded the assets acquired as part of the C2 Wellness acquisition and Alinova acquisition as indefinite lived Intangible assets. Indefinite life intangible assets recorded are not amortized and, as a result, are assessed for impairment at least annually, using either a qualitative or quantitative process. The C2 Wellness asset that was acquired was subsequently re-sold as discussed above. We performed this annual assessment as of March 31, 2024, noting impairment factors indicating possible impairment of intangible assets recognized and recorded impairment of $392,278 .
Risks and Uncertainties	Risks and Uncertainties On January 30, 2020, the World Health Organization declared the coronavirus outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the coronavirus include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and business. The Coronavirus and actions taken to mitigate it have had an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company plans to operate. We may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, and fires. An outbreak of infectious disease, a pandemic or a similar public health threat or a fear of any of the foregoing, could adversely impact us by causing operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how we may be affected if such an epidemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results, and financial condition.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Alterola does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company’s results of operations, financial position or cash flow.

NOTE 2 _ SUMMARY OF SIGNIFICA_3

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement Summary	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement Summary (Details) 3/31/2023 (as restated) 3/31/2023 Differences Assets 12,046,315 12,376,963 (330,648 ) Liabilities 2,285,171 2,281,416 3,755 Equity 9,761,144 10,095,547 (334,403 ) CTA 67,873 (63,173 ) 131,046 Result of the year (2,071,186 ) (1,742,457 ) (328,729 ) 3/31/2023 (as restated) 3/31/2023 Differences Net cash provided by operating activities (1,307,264 ) (1,039,792 ) (267,472 ) Net cash used by investing activities — (139,799 ) 139,799 Net cash provided by financing activities 1,199,073 1,212,159 (13,086 ) Net change in cash (108,191 ) 32,689 (140,880 )

NOTE 5 _ ACCOUNTS PAYABLE (Tabl

NOTE 5 – ACCOUNTS PAYABLE (Tables)	12 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
NOTE 5 - ACCOUNTS PAYABLE - Summary of Accounts Payable	March 31, 2024 March 31, 2023 Accounting and audit $ 181,955 $ 149,613 Legal fees and transfer agent 85,627 59,565 Research and development 409,904 337,893 General and administrative 147,724 66,658 Total Accrued Expenses $ 825,210 $ 613,729

NOTE 6 _ ACCRUED EXPENSES (Tabl

NOTE 6 – ACCRUED EXPENSES (Tables)	12 Months Ended
	Mar. 31, 2024
Payables and Accruals [Abstract]
NOTE 6 - ACCRUED EXPENSES - Schedule of Accrued Expenses	March 31, 2024 March 31, 2023 Accounting and Audit $ 49,468 $ 15,000 Research and development — 9,432 General and administrative 89,508 128,325 Legal fees and transfer agent 223,475 107,203 Total Accrued Expenses $ 362,451 $ 259,960

NOTE 1_ NATURE OF BUSINESS (Det

NOTE 1– NATURE OF BUSINESS (Details Narrative) - USD ($)					174 Months Ended
	Sep. 08, 2023	Apr. 18, 2023	Jan. 19, 2021	May 03, 2010	Mar. 31, 2024	Mar. 31, 2023	May 28, 2021
Liabilities					$ 1,333,264	$ 2,285,171	$ 389,721
Banking Regulation, Total Capital, Actual					1,329,601
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest					$ 12,416,075
Patent P T X [Member]
Stock Issued During Period, Shares, Acquisitions		5,000,000
Oil and Gas, Full Cost Method, Capitalized Cost Excluded from Amortization, Acquisition Cost, Period Cost		$ 35,000
Director
Stock Issued During Period, Shares, Acquisitions				55,000,000
Consulting Services
Stock Issued During Period, Shares, Acquisitions			600,000,000
C 2 Wellness Agreement Return Assets [Member]
Stock Repurchased During Period, Shares	29,015,993

NOTE 2 - SUMMARY OF SIGNIFICANT

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Restatement Summary (Details) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022	May 28, 2021
Assets	$ 3,663	$ 12,046,315
Liabilities	1,333,264	2,285,171		$ 389,721
Equity	(1,329,601)	9,761,144	$ 10,926,276
CTA	39,860	67,873
Net Income (Loss) Attributable to Parent	(2,374,379)	(2,071,186)
Net cash provided by operating activities	(1,447,088)	(1,307,264)
Net cash used by investing activities
Net cash provided by financing activities	1,468,856	1,199,073
Net change in cash	21,768	(108,191)
Difference From Restated [Member]
Assets	(330,648)
Liabilities	3,755
Equity	(334,403)
CTA	$ 131,046
Prior To Restatement [Member]
Assets		12,376,963
Liabilities		2,281,416
Equity		10,095,547
CTA		(63,173)
Net cash provided by operating activities		(1,039,792)
Net cash used by investing activities		(139,799)
Net cash provided by financing activities		1,212,159
Net change in cash		32,689
As Restated [Member]
Net Income (Loss) Attributable to Parent		(1,742,457)
Differences [Member]
Net Income (Loss) Attributable to Parent		(328,729)
Net cash provided by operating activities		(267,472)
Net cash used by investing activities		139,799
Net cash provided by financing activities		(13,086)
Net change in cash		$ (140,880)

NOTE 2 _ SUMMARY OF SIGNIFICA_4

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Accounting Policies [Abstract]
Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs	$ 0	$ 0
Impairment of Intangible Assets, Finite-Lived	$ 392,278

NOTE 3 _ INTANGIBLE ASSETS (Det

NOTE 3 – INTANGIBLE ASSETS (Details Narrative) - USD ($)	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Current			$ 12,000,000	$ 12,000,000
[custom:IntangibleAssetsCurrentAdjusted-0]		$ 12,139,779

NOTE 4 _ DEFERRED TAX ASSET (De

NOTE 4 – DEFERRED TAX ASSET (Details Narrative)	Mar. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
Deferred Tax Assets, Net of Valuation Allowance	$ 189,355

NOTE 5 - ACCOUNTS PAYABLE - Sum

NOTE 5 - ACCOUNTS PAYABLE - Summary of Accounts Payable (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Interim Period, Costs Not Allocable [Line Items]
Total Accrued Expenses	$ 825,210	$ 613,729
Accounting And Audit Fees [Member]
Interim Period, Costs Not Allocable [Line Items]
Total Accrued Expenses	181,955	149,613
Legal And Transfer Agent [Member]
Interim Period, Costs Not Allocable [Line Items]
Total Accrued Expenses	85,627	59,565
Research And Development [Member]
Interim Period, Costs Not Allocable [Line Items]
Total Accrued Expenses	409,904	337,893
General And Administrative [Member]
Interim Period, Costs Not Allocable [Line Items]
Total Accrued Expenses	$ 147,724	$ 66,658

NOTE 6 - ACCRUED EXPENSES - Sch

NOTE 6 - ACCRUED EXPENSES - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023
Interim Period, Costs Not Allocable [Line Items]
Total Accrued Expenses	$ 362,451	$ 259,960
Accounting And Audit Fees [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued Professional Fees, Current	49,468	15,000
Research And Development [Member]
Interim Period, Costs Not Allocable [Line Items]
Total Accrued Expenses		9,432
General And Administrative [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued Professional Fees, Current	89,508	128,325
Legal And Transfer Agent [Member]
Interim Period, Costs Not Allocable [Line Items]
Accrued Professional Fees, Current	$ 223,475	$ 107,203

NOTE 7 _ CAPITAL STOCK (Details

NOTE 7 – CAPITAL STOCK (Details Narrative)

1 Months Ended

12 Months Ended

Dec. 21, 2023 USD ($) shares

Oct. 16, 2023 USD ($) shares

Sep. 08, 2023 shares

Jun. 14, 2023 shares

Jun. 13, 2023 USD ($) shares

Jun. 06, 2023 shares

Aug. 01, 2022 shares

May 04, 2022 shares

May 02, 2022 USD ($) $ / shares shares

Apr. 29, 2022 USD ($) $ / shares shares

Apr. 05, 2022 USD ($) $ / shares shares

Mar. 03, 2022 USD ($) shares

Dec. 21, 2021 USD ($) shares

Nov. 09, 2021 $ / shares shares

Oct. 29, 2021 USD ($) shares

Aug. 11, 2021 $ / shares shares

Sep. 30, 2021 USD ($) shares

Mar. 31, 2024 USD ($) $ / shares shares

Mar. 31, 2023 USD ($) $ / shares shares

Dec. 31, 2022 $ / shares

Dec. 31, 2021 USD ($)

Sep. 21, 2021 GBP (£)

Accumulated Other Comprehensive Income (Loss) [Line Items]

Common Stock, Shares Authorized

2,000,000,000

2,000,000,000

Common Stock, Par or Stated Value Per Share | $ / shares

$ 0.001

$ 0.001

Preferred Stock, Shares Authorized

10,000,000

10,000,000

Preferred Stock, Par or Stated Value Per Share | $ / shares

$ 0.001

$ 0.001

Proceeds from Issuance of Common Stock | $

$ 538,324

$ 802,500

Stock Issued During Period, Value, Issued for Services | $

305,652

321,000

Intangible Assets, Current | $

12,000,000

$ 12,000,000

Stock Issued During Period, Value, Other | $

157,339

280

Stock Issued During Period, Shares, Treasury Stock Reissued

44,064,000

Stock Issued During Period, Value, Conversion of Convertible Securities | $

Contract with Customer, Asset, Allowance for Credit Loss, Writeoff | $

$ 12,000,000

[custom:StockIssuedDuringPeriodSharesConversionOfDebt]

587,499,996

[custom:LossOnExchangeOfSharesForDebt] | $

$ 406,575

[custom:TranslationAmendedAmount] | $

$ 67,873

Common Stock, Shares, Issued

1,382,662,952

807,047,948

Common Stock, Shares, Outstanding

1,382,662,952

807,047,948

August 2022 Loan Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

2,250,000

Warrant Shares [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

15,000,000

Shares Issued, Price Per Share | $ / shares

$ 0.64

Warrants and Rights Outstanding, Term

5 years

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares

$ 0.001

Class of Warrant or Right, Expense or Revenue Recognized

The total potential impact on the financial statements of the exercise of the warrants was approximately $13,500.

the total potential impact on the financial statements of the exercise of the warrants was approximately $1 million dollars

Warrants and Rights Outstanding, Maturity Date

Jun. 13, 2023

Consultancy Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares Issued, Price Per Share | $ / shares

$ 0.214

Proceeds from Issuance of Common Stock | $

$ 136,721

Stock Issued During Period, Shares, Issued for Services

1,500,000

Stock Issued During Period, Value, Issued for Services | $

$ 321,000

Subscription [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

280,000

Common Stock, Shares Subscribed but Unissued

280,000

E M C 2 Capital Services [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

7,500,000

Stock Issued During Period, Value, Issued for Services | $

$ 2,399,250

A P A Nov 9 [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares Issued, Price Per Share | $ / shares

$ 0.50

Stock Issued During Period, Shares, Acquisitions

24,000,000

Investor Issuance Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

333,333

520,000

Shares Issued, Price Per Share | $ / shares

$ 0.15

Stock Issued During Period, Value, Other | $

$ 50,000

$ 130,000

Consulting Agreement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

16,000,000

Stock Issued During Period, Value, Issued for Services | $

$ 3,360,000

Investor Issuance Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

280,000

384,615

Shares Issued, Price Per Share | $ / shares

$ 0.13

Proceeds from Issuance of Common Stock | $

$ 136,721

Stock Issued During Period, Value, Other | $

$ 50,000

Sale of Stock, Price Per Share | $ / shares

$ 0.50

Investor Issuance Three In Dollars [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Proceeds from Issuance of Common Stock | $

$ 140,000

Director Issuance [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Employee Benefit Plan

2,250,000

E M C 2 Capital L L C [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Value, Conversion of Convertible Securities | $

$ 13,500,000

Stock Redeemed or Called During Period, Shares

15,000,000

Alison Burgess [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Other

476,000

Loans Payable | £

£ 125,000

Alinova Biosciences [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Acquisitions

5,000,000

Long Eight Limited [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

5,999,900

Warren Law Group [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

10,088,100

Directors [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Employee Benefit Plan

9,000,000

C 2 Wellness Agreement Return Assets [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Repurchased During Period, Shares

29,015,993

C 2 Wellness Agreement Return Assets Initially Issued [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Repurchased During Period, Shares

24,000,000

C 2 Wellness Agreement Return Assets Additionally Issued [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Repurchased During Period, Shares

5,015,996

Dec 2023 Services [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, Issued for Services

17,131,001

Stock Issued During Period, Value, Issued for Services | $

$ 61,672

NOTE 8 _ NOTES PAYABLE (Details

NOTE 8 – NOTES PAYABLE (Details Narrative)				5 Months Ended	12 Months Ended
	Jun. 13, 2023 $ / shares shares	Aug. 01, 2022 shares	Sep. 21, 2021 USD ($) shares	Dec. 23, 2022 USD ($)	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Jul. 18, 2022 USD ($)	Sep. 21, 2021 GBP (£)
Short-Term Debt [Line Items]
Stock Issued During Period, Value, Other					$ 157,339	$ 280
Loans Payable, Current					$ 145,603	$ 1,256,641
Alison Burgess [Member]
Short-Term Debt [Line Items]
Stock Issued During Period, Shares, Other | shares	476,000
Loans Payable | £								£ 125,000
Note Payable One [Member]
Short-Term Debt [Line Items]
Proceeds from Notes Payable			$ 171,863
Debt Instrument, Term			90 days
Debt Instrument, Interest Rate Terms			with an interest fee of $13,680
Debt Instrument, Convertible, Terms of Conversion Feature			The conversion option would be at 90 days, with share conversion at .50 cents, with an issuance of 340,000 shares, valued at $428,400 at the date of the loan
Debt Conversion, Converted Instrument, Shares Issued | shares	476,000
Debt Conversion, Converted Instrument, Rate	60%
Debt Instrument, Convertible, Stock Price Trigger | $ / shares	$ 1.37
Note Payable One Share Bonus [Member]
Short-Term Debt [Line Items]
Stock Issued During Period, Shares, Other | shares			136,000
Stock Issued During Period, Value, Other			$ 171,000
Note Payable Two [Member]
Short-Term Debt [Line Items]
Debt Instrument, Term		90 days
Loans Payable, Current							$ 75,000
Common Stock, Shares Subscribed but Unissued | shares		2,250,000
Repayments of Long-Term Loans from Vendors				$ 75,000

NOTE 9 _ RELATED PARTY TRANSA_2

NOTE 9 – RELATED PARTY TRANSACTIONS (Details Narrative)	12 Months Ended
	Mar. 31, 2024 USD ($)
Related Party Transaction [Line Items]
[custom:ShareholderAdvances]	$ 694,847
Shareholder Advances [Member]
Related Party Transaction [Line Items]
Debt Instrument, Description	These advances are non – interest bearing and have no specified terms of repayment